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VEGF expression in the placenta from pregnancies complicated
by hypertensive disorders
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Objective To determine the expression of VEGF in the placental tissue from pregnancies complicated by
hypertension disorders of different clinical severity.
Design Prospective cohort study.
Setting Polyclinic of Careggi, University of Florence, Italy.
Sample Placentas from women with gestational hypertension (n ¼ 20), pre-eclampsia (n ¼ 20) and pre-
eclampsia with HELLP syndrome (n ¼ 20) and from normotensive women (n ¼ 20), as control group
(gestational age comprised between 35 and 38 weeks).
Methods An immunohistochemical technique and a quantitative analysis to measure mRNA levels (RT-PCR)
were employed.
Main outcome measures Intensity of immunoreactivity and mRNA levels in the placental components.
Differences between the data.
Results VEGF immunoreactivity was observable in all the placental components in the gestational
hypertension cases as in the control ones. In the cases with pre-eclampsia and pre-eclampsia with HELLP
syndrome, some placental components were not immunoreactive. However, the VEGF positive components
of all the pathological groups showed a higher intensity of reactivity with respect to that of the control
group. The levels of VEGF mRNA were higher in the gestational hypertension cases and lower in the cases
of pre-eclampsia with HELLP syndrome with respect to the control ones; in the cases of pre-eclampsia, the
levels were the same as the control ones.
Conclusion The different expression of VEGF in the placenta of the pathological cases is probably related to
haemodynamic changes that take place in these disorders, in order to attempt restoration of a normal
uteroplacental flow.
INTRODUCTION
In physiological pregnancies, successful placentation
involves the development of a low-impedance uteroplacen-
tal circulation after trophoblast invasion and transformation
of the maternal intramyometrial portion of the spiral
arterioles.1,2 In pregnancies complicated by pre-eclampsia,
trophoblast invasion of the spiral arterioles is abnormal,
resulting in impaired uteroplacental perfusion (‘placental
hypoxia’ theory).3–6 This in turn results in the release
of factors into the maternal circulation that may be re-
sponsible in endothelial dysfunction, vasoconstriction and
hypertension.4,6,7
Vascular endothelial growth factor (VEGF) is a disul-
phide-linked homodimeric glycoprotein that is selectively
mitogenic for endothelial cells and appears to play a major
role in the mediation of vasculogenesis, angiogenesis, in
the control of the microvascular permeability and of the
vasodilatation.8–14 Hypoxia is a potent stimulus for induc-
tion of VEGF gene expression and has been shown to
increase the stability of VEGF mRNA.12,15,16 VEGF and
other factors are likely to be involved in the uterine vessels
remodelling and in the angiogenesis which occurs during
the growth of the placenta throughout pregnancy.10,17,18
Another important role has been postulated for VEGF in
the regulation of the trophoblast invasion, proliferation and
differentiation.15,18–24 In the human placenta, this factor
has chiefly been identified in the villous cytotrophoblast in
the first trimester and in the syncytiotrophoblast and extra-
villous trophoblast in the term placenta.8,10
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Various studies have been carried out on the plasma or
serum concentration of VEGF and its expression in the
placental tissue of women with pregnancies complicated
by hypertensive disorders. Several investigations have
shown that VEGF concentrations are increased in the
plasma or serum of women with pregnancies complicated
by hypertensive disorders compared with normotensive
women, although this is not confirmed in other studies.25–34
Studies of the placental VEGF immunostaining in preg-
nancies complicated by more or less severe hypertensive
disorders have reported a decrease of this factor, while
in another study an increase has been observed.26,31,35
Investigations on the mRNA of VEGF have shown that
its levels were lower in pre-eclamptic placentas com-
pared with control placentas36; other studies have dem-
onstrated either an increase or no evidence of abnormal
placental VEGF expression in pregnancies complicated
by pre-eclampsia.31,37
The aim of this study was to evaluate the expression of
the VEGF in placentas from pregnancies complicated by
hypertensive disorders of different clinical severity, in an
attempt to clarify these disagreements.
METHODS
Three study groups were considered: (1) a first study
group of women with pregnancies complicated by gesta-
tional hypertension (n ¼ 20); (2) a second study group of
women with pregnancies complicated by pre-eclampsia
(n ¼ 20); (3) a third study group of women with pregnan-
cies complicated by pre-eclampsia with HELLP syndrome
(n ¼ 20). Women with uncomplicated pregnancies (n ¼ 20)
were examined as control group. The gestational age was
comprised between 35 and 38 weeks.
No women with chronic hypertension, renal disease or
diabetes were included. Women in all the study groups
were delivered by caesarean route. Controls were women
undergoing cesarean section on one of the following
indications: breech presentation, cephalopelvic dispropor-
tion or psychological reasons.
Gestational hypertension was defined as persistent dia-
stolic blood pressure above 90 mmHg and systolic blood
pressure above 140 mmHg in normotensive patients be-
fore 20 weeks of gestation. Criteria for diagnosis of pre-
eclampsia were: diastolic blood pressure above 90 mmHg
and systolic blood pressure above 140 mmHg, with oedema
and proteinuria greater than 0.3 g/24 h in normotensive
patients before 20 weeks of gestation. Criteria for diagnosis
of the HELLP syndrome were: (1) haemolysis: abnormal
peripheral blood smear, total bilirubin 1.2 mg/dL, lactic
dehydrogenase (LDH) 600 U/L; (2) elevated liver en-
zymes: serum aspartate aminotransferase (AST) 70 U/L;
(3) low platelets: platelets count 100,000/AL.
Informed written consent was obtained from each
patient.
At delivery, the placentas were weighed and full thick-
ness blocks were obtained. A stratified random sampling
procedure was used to obtain 12 blocks of full thickness
tissue per organ. Six specimens were immersed in neutral
4% buffered formalin solution for 12 hours and processed
in a standard manner for the preparation of paraffin blocks;
sections of 5 Am thickness were then obtained. The other
specimens were snap frozen without delay in liquid nitro-
gen and stored in 80jC.
The sections were treated according to the standard
immunohistochemical technique for detection of VEGF.
Endogenous peroxidase was blocked by incubation of the
sections in 0.3% hydrogen peroxide. The samples were
incubated with blocking serum to reduce non-specific
reactions and then incubated with the primary antibody.
The VEGF antibody used was a monoclonal mouse anti-
humane VEGF (Santa Cruz, California, USA) at a dilution
of 1:80. The remaining procedure was performed using the
mouse ABC kit Staining Systems (Santa Cruz, California,
USA). Immunoreactive VEGF was localised by incubating
sections in 0.7 mg/mL 3,3V-diaminobenzidine and 0.7 mg/
mL hydrogen peroxide in 0.06 M TBS. Ten fields were
examined for each section by an investigator blinded to the
tissue identity and scored for location of staining in
trophoblast, stromal cells, Hofbauer cells and vessels. All
sections were stained in the same batch to eliminate inter-
batch variations.
RNA extraction from the frozen specimens was per-
formed by disruption in 600 AL of guanidine isothiocya-
nate-containing lysis Qiagen buffer (QIAGEN, Milan,
Italy) added with h-merchaptoethanol. Total RNA was
extracted with Rneasy MiniKit Qiagen columns and treated
with Rnase free DNAse Set QIAGEN. RNA was then
eluted from columns with 50 AL Rnase free water. Total
RNA was determined with the Pharmacia GeneQuant
spectrophotometer.
A standard RNA preparation for the proposed VEGF
RT-PCR assay was obtained by a conventional phenol–
chloroform extraction from V-12 cells, over-expressing
VEGF. The amount of the extracted RNA was evaluated
spectrophotometrically and then the concentration of the
VEGF mRNA was accurately determined by a competitive
RT-PCR assay. For this purpose, a synthetic internal
standard was constructed by the oligonucleotide overlap
extension technique. Details about this procedure have been
previously described.38,39 Aliquots of the VEGF mRNA for
the standard curve were stored at 80jC. In each assay, a
VEGF mRNA amount in the range 2.5  109–2.5  104
molecules was used for standard curve. Finally, results of
the VEGF mRNA concentration were expressed in terms of
VEGF mRNA molecules/Ag total RNA.
All reagents both for reverse transcription and amplifi-
cation were from Applied Biosystem (Foster City, Califor-
nia, USA). Fifty nanograms of extracted mRNA from the
standard preparation and from human specimens were
reverse-transcribed using the TaqMan Reverse Trascription
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Reagents Kit. According to the kit instructions, reagents
were prepared to give final concentration of 1 TaqMan
RT-buffer, 2.5 mM random hexamers, 500 mM each dNTP,
5.5 mM MgCl2 and 1.25 U/mL, Multiscribe TM reverse
transcriptase in a final volume of 20 AL. Retrotranscription
was performed using the following programme: 10 minutes
25jC, 30 minutes at 48jC, 5 minutes at 95jC. Subsequent-
ly, 5 AL of the RT sample was amplified. The PCR mix
contained TaqMan Universal Master Mix, 300 nmol/L each
primer and 200 nmol/L probe. VEGF mRNA was amplified
by a first step of 2 minutes at 50jC, 10 minutes at 95jC
followed from 40 cycles of 15 seconds at 95jC, 1 minute at
60jC. All the RT-PCR reactions were performed in the ABI
PRISM 7700 Sequence Detector in a 25 AL final volume.
Standard curve and samples were carried out in triplicates.
Primers for the real-time RT-PCR assay, selected using
the proprietary software Primer Express (Applied Bio-
system), were: 5V-TACCTCCACCATGCCAAGTG-3V (for-
ward primer), 5V-ATGATTCTGCCCTCCTCCTTC-3V
(reverse primer). The sequence of the fluorogenic probe
(FAM) was: 5V-TCCCAGGCTGCACCCATGGC-3V.
To compare clinical data between the study groups, the
one-way ANOVA and ANOVA for rank, when appropriate,
were applied.
The t test for paired samples was used to test differences
between the data on the VEGF mRNA concentrations of
the control group and those of the other study groups.
Probability of less than 0.05 (P < 0.05) was considered
statistically significant.
For each section VEGF immunostained, a statistical
analysis was also performed to evaluate the intensity of
immunoreactivity in the trophoblast, in the wall vessels, in
the stromal cells and in the Hofbauer cells. For this
purpose, the optical density was measured on grey scale
images using a computerised image analyser programme
(Image-Pro Plus v. 4.5, Media Cybernetics, Silver Spring,
Maryland, USA). The staining intensity was measured and
expressed in arbitrary units standardised from 0 to 250,
0 being the maximum of the staining and 250 no staining.
Ten fields for each section, selected at random, were
examined and two types of measurements were performed
for each placental component and for each field: a mea-
surement of intensity only of the components reactive and a
measurement of intensity of all the components (reactive
and not reactive) observed in the field. Statistical analysis
was performed using the t test for paired samples (P < 0.05
was considered significant). Then the following were
tested: (1) differences between the data obtained from
the first type of measurement of the control group and
those of the other groups; (2) differences between the data
obtained from the first and the second type of measure-
ment in each study group. All the sections were examined
by a single observer blinded to the origin of the organ
under study. The reproducibility of the measuring analysis
was assessed by comparing the measurements made by one
observer at different times, and the measurements of two
observers. Intra-observer and inter-observer coefficients of
variation were 1.5% and 5.2%, respectively.
RESULTS
The clinical details of the women whose placentas were
used for this study are reported in Table 1. Mean weeks of
gestation at delivery was significantly lower in the cases
with pre-eclampsia and with pre-eclampsia with HELLP
Table 1. Clinical details of the study groups. Values shown are mean (SEM), unless otherwise indicated.
Control (n ¼ 20)a Hypertension (n ¼ 20)b Pre-eclampsia (n ¼ 20)c Pre-eclampsia/HELLP
syndrome (n ¼ 20)d
(1) Maternal age (years) 30.2 (7.4) 31.0 (8.3) 30.2 (5.8) 29.4 (6.1)
(2) Gestation at delivery (weeks) 38.0 (1.3) 37.8 (1.8) 35.1 (5.9)* 35.0 (4.0)*
(3) Birthweight (g) 3480.1 (610.1) 3310.4 (712.2) 2240.2 (318.1)* 2080.1 (428.2)*
(4) Placenta weight (g) 618.8 (80.1) 524.4 (59.1) 412.4 (64.3)** 385.2 (52.7)**
(5) Primigravidae (n) 12 10 10 12
(6) Smokers (n) 4 12 4 4
(7) Pregnancy BMI 22.4 (2.3) 24.8 (3.2) 23.5 (3.2) 24.1 (4.1)
Blood pressure at delivery (mmHg)
(8) Systolic 111.2 (9.3) 148.8 (9.1)* 155.2 (10.3)* 147.2 (8.2)*
(9) Diastolic 65.7 (8.2) 97.3 (6.5)* 101.4 (10.1)* 97.4 (7.4)*
BMI ¼ body mass index; (2) c, d versus a, b: *P < 0.005; (3) c, d versus a, b: *P < 0.005; (4) c, d versus a, b: **P < 0.05; (8) c versus b, d versus a: *P <
0.005; (9) c versus b, d versus a: *P < 0.005.
Table 2. Assessment of VEFG immunostaining in the placenta.
Study groups Trophoblast Vessels Stromal
cells
Hofbauer
cells
Control þ þ þ þ
Hypertension þ þ þ þ
Pre-eclampsia þ* þ þ þ
Pre-eclampsia/HELLP
syndrome
þ* þ** þ§ þ
þ ¼ Reactivity; * ¼ Reactivity in some tracts of trophoblast; ** ¼
Reactivity in some vessels; § ¼ Reactivity in cell clusters.
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syndrome (P < 0.005) with respect to the other cases. Mean
birthweight (P < 0.005) and placenta weight (P < 0.05)
were significantly lower in the cases with pre-eclampsia
and pre-eclampsia with HELLP syndrome with respect to
the others. Mean pressure (systolic and diastolic) was statis-
tically higher (P < 0.005) in the cases with pre-eclampsia
when compared with the cases with hypertension and with
pre-eclampsia with HELLP syndrome; these last two cases
showed mean values significantly higher (P < 0.005) with
respect to the cases of control. The other clinical data did
not show significant differences between study groups.
The study was limited to the chorionic intermediate and
terminal villi (Table 2).
Control group: The trophoblast, the endothelial cells of the
vessels, the stromal cells and the Hofbauer cells showed
immunoreactivity (Fig. 1).
Hypertensive disorders groups: In the cases of gestational
hypertension (Fig. 2) and of pre-eclampsia (Fig. 3), the
various placental components were immunoreactive,
although in the pre-eclampsia some tracts of trophoblast
were not reactive.
In the cases of pre-eclampsia with HELLP syndrome, the
trophoblast of the placenta showed reactivity, but only in
some tracts. The endothelial cells of some vessels were
reactive, while those of other vessels showed no reactivity.
Fig. 1. VEGF immunostaining: Control, 38 weeks. The trophoblast, the
endothelial cells of the vessels, the stromal cells and the Hofbauer cells
(arrows) show reactivity. Original magnification 1000.
Fig. 2. VEGF immunostaining: Hypertension, 37 weeks. Reactivity is
observed in the trophoblast, the stromal cells, the endothelial cells of the
vessels and in one Hofbauer cell (arrow). Original magnification 1000.
Fig. 3. VEGF immunostaining: Pre-eclampsia, 36 weeks. Some tracts of
trophoblast, the endothelial cells of the vessels, the stromal cells and one
Hofbauer cell (arrow) show reactivity. Original magnification 1000.
Fig. 4. VEGF immunostaining: Pre-eclampsia/HELLP syndrome, 36
weeks. Few tracts of trophoblast and the endothelial cells of some vessels
are reactive. Two Hofbauer cells (arrows) show also reactivity. Original
magnification 1000.
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In the stroma cell clusters and the Hofbauer cells were
reactive (Fig. 4).
The statistical analysis with regard to the first type of
measurement showed that the intensity of immunoreactiv-
ity of the trophoblast was higher in the cases of hyper-
tension (P < 0.001), of pre-eclampsia (P < 0.05) and of
pre-eclampsia with HELLP syndrome (P < 0.005) with
respect to the control group. The intensity of reactivity of
the vessels was significantly higher in the cases of hyper-
tension (P < 0.05) and of pre-eclampsia with HELLP syn-
drome (P < 0.05) when compared with the control group;
the vessels of the cases of pre-eclampsia did not show
significant differences in reactivity with respect to those of
the control group. The reactivity of the stromal cells was
significantly higher in all the pathological cases (hyperten-
sion and pre-eclampsia with HELLP syndrome: P < 0.001;
pre-eclampsia: P < 0.01). The Hofbauer cells showed a
reactivity significantly higher in the cases of pre-eclampsia
with HELLP syndrome when compared with the control
group (P < 0.01). The Hofbauer cells of the other patho-
logical cases did not show significant differences in reac-
tivity with respect to the control group. The data obtained
from the first type of measurement did not show significant
differences when compared with those of the second type
of measurement in the control group and in the cases of
hypertension. In the cases of pre-eclampsia, the data of the
second measurement on the trophoblast were significantly
lower with respect to those of the first measurement (P <
0.001), while the data of the two measurements on the
other placental components did not show significant differ-
ences. In the cases of pre-eclampsia with HELLP syn-
drome, the data of the second measurement on the
trophoblast (P < 0.001), on the vessels (P < 0.05) and
on the stromal cells (P < 0.001) were significantly lower
with respect to those of the first measurement; the data of
the two measurements on the Hofbauer cells did not show
significant differences.
No statistically significant difference was revealed on
the placental mRNA levels of VEGF in the cases of pre-
eclampsia when compared with the mRNA levels in the
control group (P ¼ 0.4). In the cases of pre-eclampsia
with HELLP syndrome the levels were statistically lower
(P < 0.005) and in those of hypertension were higher (P <
0.0005) with respect to the control ones (Table 3).
DISCUSSION
This is the first study that investigates the expression of
VEGF in the placenta from pregnancies complicated by
hypertension disorders with various degrees of clinical
severity. The data obtained in these cases were compared
with those obtained in a group of physiological pregnancies
considered as control group.
With regards the control group, our immunohisto-
chemical results showed that VEGF was expressed in
various placental components as observed in previous
studies.17,26,35,40 Moreover, in our study, VEGF immuno-
reactivity was also detected in the endothelial cells of the
vessels that have not been observed previously. It is to be
noted that in a study in vitro on the endothelial cells, an
autocrine secretion of VEGF by these cells has been
observed.41 Therefore, VEGF immunoreactivity, which
was present in the endothelial cells of the vessels, might
be due to both the binding to its receptors and the
production of this factor by these cells.
Our data on the determination of the presence of VEGF
mRNA in the control group confirm the results of previous
investigations, although the levels are not comparable
because of the different assays employed.8,18,36–38,42
In the hypertension disorders groups, the location of
VEGF in the placenta was the same with respect to the
control group. In the cases of pre-eclampsia and, in partic-
ular, in the cases of pre-eclampsia with HELLP syndrome,
some components did not express this factor, as demon-
strated by the simple morphological observation and by the
comparison of the data of the two types of measurements
in each study group. However, the intensity of immuno-
rectivity of the VEGF positive components was signifi-
cantly higher in all the pathological groups with respect to
the control one.
The VEGF mRNA levels in the cases of hypertension
showed a statistically significant increase with respect to
those of the control group. However, in pre-eclampsia, the
levels of VEGF mRNA were not statistically different
when compared with those of the control group, while in
the pre-eclampsia with HELLP syndrome the levels were
statistically lower.
These findings might be related to the different degrees
of clinical severity of the various hypertensive disorders.
It is known that in placentas from pregnancies with
hypertension disorders, a hypoperfusion occurs followed
by a hypoxic environment that stimulates the VEGF
production.3–6,12,15,16 Therefore, in the placenta of preg-
nancies with gestational hypertension, that are the lesser
severe clinical cases, an increase of placental VEGF might
be a compensatory mechanism in attempting to restore the
blood flow toward normal. In the pregnancies with pre-
eclampsia and with pre-eclampsia with HELLP syndrome,
that according to some authors is a complication of the pre-
eclampsia but in the opinion of others it can be also a
separate entity,43–48 there is also probably an attempt of
Table 3. Values of mRNA concentration in the placenta. Values shown
are mean (SEM).
Study groups
VEGF mRNA molecules/Ag
total RNA
Control 4.31  107 (3.36  106)
Hypertension 3.29  108 (3.71  107)*
Pre-eclampsia 4.61  107 (3.01  106)
Pre-eclampsia/HELLP syndrome 1.99  107 (2.33  106)**
* Hypertension versus control: P < 0.0005.
** Pre-eclampsia/HELLP syndrome versus control: P < 0.005.
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compensatory mechanism, but only some placental com-
ponents seem be able to produce VEGF, as shown by
immunohistochemistry. In some studies, it has been seen
that VEGF, increasing in production with other factors,
might have led to morphological and physiological alter-
ations of the placental tissue that characterise the pre-
eclampsia.29,30,32,49–53 Therefore, in pre-eclampsia and in
particular in pre-eclampsia with HELLP syndrome, there
is probably an overproduction of VEGF in a definite period
of gestation that might have led to the alteration and
damage of the placental tissue, and then only some com-
ponents might continue to overproduce VEGF. This fact
might account for the lower levels of VEGF mRNA
detected in these cases with respect to those in the cases
of hypertension.
In previous studies on the expression of VEGF in
placentas from pregnancies complicated by pre-eclampsia,
a discrepancy of data was observed.26,31,36 Our findings
are partially in agreement with those of some of these
investigations.31,35,37,48 These disagreements might be due
to an assemblage in one study group of cases of hyperten-
sive disorders with different degrees of clinical severity
and/or with a wide gestational age range and/or to an
incorrect sampling of the tissue by the various authors. In
our study, we attempted to form homogenous study groups
of hypertensive disorders with a limited range of gesta-
tional age and we made a sampling random of the placental
tissue in order to have a representative material of the
whole organ for each case.
In conclusion, our data demonstrated that placental
tissue from pregnancies with hypertensive disorders
showed a different expression of VEGF according to
different degrees of clinical severity.
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